600829.SHG HPGC Renmintongtai Pharmaceutical Corp
- Market cap
- CNY 5.17B
- P/E
- 31.8x
- P/B
- 1.62x
- ROE
- 5.8%
- Dividend yield
- 0.39%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600829.SHG undervalued?
Graham number600829.SHG trades 51.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HPGC Renmintongtai Pharmaceutical Corp fundamental analysis
No fundamental analysis for HPGC Renmintongtai Pharmaceutical Corp yet.
HPGC Renmintongtai Pharmaceutical Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HPGC Renmintongtai Pharmaceutical Corp
HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers chemical drugs, traditional Chinese medicine, biological products, and medical supplies; medical instruments, traditional Chinese medicine decoction pieces, health foods, daily necessities, glassware, and chemical reagents, etc.; It serves its products through e-commerce platforms, direct sales, and a chain of direct st…
Full company profileHPGC Renmintongtai Pharmaceutical Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
HPGC Renmintongtai Pharmaceutical Corp annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.01B | 8.01B | 7.06B | 8.35B | 8.01B | 9.32B | 9.64B | 10.4B | 10.0B | 10.4B | 10.8B |
| Gross Profit | 887M | 915M | 890M | 1.00B | 904M | 985M | 907M | 986M | 858M | 854M | 893M |
| Operating Income | 323M | 339M | 350M | 364M | 220M | 361M | 347M | 399M | 289M | 290M | 329M |
| EBITDA | 342M | 392M | 402M | 417M | 280M | 438M | 421M | 450M | 344M | 273M | 273M |
| Net Income | 225M | 254M | 258M | 267M | 145M | 277M | 264M | 292M | 213M | 134M | 182M |
| EPS | 0.39 | 0.44 | 0.44 | 0.46 | 0.25 | 0.48 | 0.46 | 0.50 | 0.37 | 0.23 | 0.31 |
| Balance Sheet | |||||||||||
| Total Assets | 4.81B | 4.84B | 4.41B | 5.55B | 6.00B | 6.75B | 7.06B | 7.43B | 7.17B | 7.17B | 7.41B |
| Total Liabilities | 3.16B | 3.23B | 2.83B | 3.70B | 4.00B | 4.55B | 4.60B | 4.68B | 4.29B | 4.16B | 4.26B |
| Shareholders' Equity | 1.65B | 1.61B | 1.58B | 1.85B | 1.99B | 2.20B | 2.46B | 2.75B | 2.88B | 3.02B | 3.15B |
| Cash & Short-term Investments | 494M | 443M | 506M | 367M | 417M | 800M | 1.18B | 1.31B | 1.10B | 1.24B | 663M |
| Total Debt | 110M | 224M | 224M | 524M | 611M | 1.33B | 1.27B | 991M | 870M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 46.0M | 139M | 366M | -412M | -9.22M | -233M | 307M | 333M | 115M | 300M | - |
| Capital Expenditure | 22.8M | 7.10M | 5.73M | 8.33M | 14.0M | 12.2M | 6.42M | 23.5M | 8.04M | 17.2M | 26.8M |
| Free Cash Flow | 23.2M | 132M | 361M | -420M | -23.2M | -245M | 301M | 310M | 107M | 283M | -601M |
| Ratios | |||||||||||
| ROE | 13.6% | 15.8% | 16.3% | 14.5% | 7.3% | 12.6% | 10.7% | 10.6% | 7.4% | 4.4% | 5.8% |
| ROA | 4.7% | 5.3% | 5.8% | 4.8% | 2.4% | 4.1% | 3.7% | 3.9% | 3.0% | 1.9% | 2.5% |
| Net Profit Margin | 2.5% | 3.2% | 3.7% | 3.2% | 1.8% | 3.0% | 2.7% | 2.8% | 2.1% | 1.3% | 1.7% |
| Debt to Equity | 0.07x | 0.14x | 0.14x | 0.28x | 0.31x | 0.60x | 0.51x | 0.36x | 0.30x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
HPGC Renmintongtai Pharmaceutical Corp dividends
- Dividend yield
- 0.39%
- Forward dividend
- -
- Payout ratio
- 15.0%
- Ex-dividend date
- Jul 25, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 20.1M | 0.03 | 15.0% |
| 2024 | CNY 160M | 0.28 | 75.2% |
| 2023 | CNY 24.6M | 0.04 | 8.4% |
| 2022 | CNY 30.5M | 0.05 | 11.5% |
| 2021 | CNY 69.6M | 0.12 | 25.1% |
| 2020 | CNY 4.26M | 0.01 | 2.9% |
| 2019 | CNY 14.2M | 0.02 | 5.3% |
| 2018 | CNY 299M | 0.51 | 116.0% |
| 2017 | CNY 297M | 0.51 | 116.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 15:10 on Jun 14, 2011.
Who owns HPGC Renmintongtai Pharmaceutical Corp
- Insiders 75.37%
- Institutions 0.82%
- Public & others 23.81%
- Shares outstanding 580M
- Free float 147M
HPGC Renmintongtai Pharmaceutical Corp company profile
- Company name
- HPGC Renmintongtai Pharmaceutical Corp
- Ticker
- 600829.SHG
- ISIN
- CNE000000G05
- Exchange
- Shanghai Stock Exchange
- Listed since
- Jan 12, 1994
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 2,735
- Fiscal year end
- December
- Address
- No. 418 Haiyao Road, Harbin, China, 150076
- Phone
- 86 45 1846 00888
- Website
- hyrmtt.com.cn
About HPGC Renmintongtai Pharmaceutical Corp
HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers chemical drugs, traditional Chinese medicine, biological products, and medical supplies; medical instruments, traditional Chinese medicine decoction pieces, health foods, daily necessities, glassware, and chemical reagents, etc.; It serves its products through e-commerce platforms, direct sales, and a chain of direct stores and online B2C, O2O, etc. The company was founded in 1950 and is headquartered in Harbin, China. HPGC Renmintongtai Pharmaceutical Corporation is a subsidiary of Harbin Pharmaceutical Group Co., Ltd.
HPGC Renmintongtai Pharmaceutical Corp management
3- Mr. Weidong ZhuGM & Chairman of the Board · born 1969
- Ms. Ping GuanDeputy GM & CFO · born 1972
- Mr. Lei WangBoard Secretary · born 1982